These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 38501315

  • 1. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease.
    Huang SY, Zhang YR, Guo Y, Du J, Ren P, Wu BS, Feng JF, Alzheimer's Disease Neuroimaging Initiative, Cheng W, Yu JT.
    Alzheimers Dement; 2024 May; 20(5):3251-3269. PubMed ID: 38501315
    [Abstract] [Full Text] [Related]

  • 2. Impaired Glymphatic Flow on Diffusion Tensor MRI as a Marker of Neurodegeneration in Alzheimer's Disease: Correlation with Gray Matter Volume Loss and Cognitive Decline Independent of Cerebral Amyloid Deposition.
    Kim M, Song YS, Han K, Bae YJ, Han JW, Kim KW.
    J Alzheimers Dis; 2024 May; 99(1):279-290. PubMed ID: 38669532
    [Abstract] [Full Text] [Related]

  • 3. Glymphatic system impairment in Alzheimer's disease: associations with perivascular space volume and cognitive function.
    Zhang X, Wang Y, Jiao B, Wang Z, Shi J, Zhang Y, Bai X, Li Z, Li S, Bai R, Sui B.
    Eur Radiol; 2024 Feb; 34(2):1314-1323. PubMed ID: 37610441
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's disease continuum participants.
    Hong H, Hong L, Luo X, Zeng Q, Li K, Wang S, Jiaerken Y, Zhang R, Yu X, Zhang Y, Lei C, Liu Z, Chen Y, Huang P, Zhang M, Alzheimer’s Disease Neuroimaging Initiative (ADNI).
    Alzheimers Res Ther; 2024 Feb 20; 16(1):43. PubMed ID: 38378607
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Unveiling the link between glymphatic function and cortical microstructures in post-traumatic stress disorder.
    Shao Z, Gao X, Cen S, Department of Defense Alzheimer's Disease Neuroimaging Initiative, Tang X, Gong J, Ding W.
    J Affect Disord; 2024 Nov 15; 365():341-350. PubMed ID: 39178958
    [Abstract] [Full Text] [Related]

  • 12. Impaired glymphatic function as a biomarker for subjective cognitive decline: An exploratory dual cohort study.
    Li Y, Wang L, Zhong J, Xu H, Han Y, Alzheimer's Disease Neuroimaging Initiative, Zuo C, Jiang J.
    Alzheimers Dement; 2024 Sep 15; 20(9):6542-6555. PubMed ID: 39107995
    [Abstract] [Full Text] [Related]

  • 13. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
    d'Oleire Uquillas F, Jacobs HIL, Hanseeuw B, Marshall GA, Properzi M, Schultz AP, LaPoint MR, Johnson KA, Sperling RA, Vannini P.
    Neuroimage Clin; 2018 Sep 15; 17():388-396. PubMed ID: 29159051
    [Abstract] [Full Text] [Related]

  • 14. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Alzheimer's Disease Neuroimaging Initiative.
    Brain; 2010 Nov 15; 133(11):3336-48. PubMed ID: 20935035
    [Abstract] [Full Text] [Related]

  • 15. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging.
    Ottoy J, Niemantsverdriet E, Verhaeghe J, De Roeck E, Struyfs H, Somers C, Wyffels L, Ceyssens S, Van Mossevelde S, Van den Bossche T, Van Broeckhoven C, Ribbens A, Bjerke M, Stroobants S, Engelborghs S, Staelens S.
    Neuroimage Clin; 2019 Nov 15; 22():101771. PubMed ID: 30927601
    [Abstract] [Full Text] [Related]

  • 16. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM, Fripp J, Rowe CC, Villemagne VL, Salvado O, Rose S, Coulson EJ, Alzheimer's Disease Neuroimaging Initiative.
    Neuroimage Clin; 2015 Nov 15; 7():105-13. PubMed ID: 25610772
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
    Zhang H, Lyu D, Jia J, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2022 Nov 15; 85(4):1441-1452. PubMed ID: 34958042
    [Abstract] [Full Text] [Related]

  • 19. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y, Raichle ME, Wen J, Benzinger TL, Fagan AM, Hassenstab J, Vlassenko AG, Luo J, Cairns NJ, Christensen JJ, Morris JC, Yablonskiy DA.
    Neuroimage; 2017 Mar 01; 148():296-304. PubMed ID: 27989773
    [Abstract] [Full Text] [Related]

  • 20. Biological mechanisms of resilience to tau pathology in Alzheimer's disease.
    Svenningsson AL, Bocancea DI, Stomrud E, van Loenhoud A, Barkhof F, Mattsson-Carlgren N, Palmqvist S, Hansson O, Ossenkoppele R.
    Alzheimers Res Ther; 2024 Oct 12; 16(1):221. PubMed ID: 39396028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.